What is Think Bioscience?
Think Bioscience operates at the intersection of advanced engineering and medicinal chemistry. The company focuses on the discovery and development of small molecule therapeutics, specifically targeting biological pathways that have historically resisted traditional drug development methodologies. By utilizing a proprietary platform that integrates applied enzymology and computational modeling, the firm identifies novel chemical entities capable of modulating complex targets. This approach allows the company to bypass the limitations of conventional screening, effectively opening new frontiers in precision medicine and therapeutic intervention.
How much funding has Think Bioscience raised?
Think Bioscience has raised a total of $73.9M across 3 funding rounds:
Angel/Pre-Seed
$1.9M
Seed
$17M
Series A
$55M
Angel/Pre-Seed (2021): $1.9M, investors not publicly disclosed
Seed (2022): $17M led by AV8 Ventures, Innovation Endeavors, and Xora Innovation
Series A (2026): $55M supported by AV8 Ventures, Crescent Enterprises, Janus Henderson Investors, MBX Capital, Colorado Venture Partners, Innovation Endeavors, and Regeneron Ventures
Key Investors in Think Bioscience
AV8 Ventures
AV8 Ventures is an investment firm that supports early-stage start-ups in sectors such as healthcare, enterprise, financial services, and deep-tech, partnering with founders to build category-defining companies.
Innovation Endeavors
Innovation Endeavors is an early-stage venture capital firm that invests in visionary founders and transformational technologies, utilizing a Super Evolution thesis to bridge data and life sciences.
Regeneron Ventures
Regeneron Ventures focuses on investing in innovative biotechnology and pharmaceutical companies to support the development of groundbreaking therapies and improve patient outcomes.
What's next for Think Bioscience?
With the successful closure of its Series A round, Think Bioscience is poised to transition its lead programs into more advanced stages of development. The strategic capital will likely be deployed to scale its computational infrastructure and expand its laboratory capabilities in Colorado. As the company matures, the focus will shift toward validating its lead candidates in preclinical models and establishing potential partnerships with larger pharmaceutical entities to facilitate clinical trials. The firm's ability to maintain a robust pipeline of first-in-class assets will be critical as it seeks to solidify its market position within the competitive landscape of modern drug discovery.
See full Think Bioscience company page
